All

Results: 9901-9912 of 70878

PR Newswire associated0

Binance Launches First Regulated TradFi Perpetual Contracts Settled in Stablecoin, Starting with Gold and Silver

Experience Japanese Culture and Art at Keio Plaza Hotel Tokyo through Workshop Program Scheduled from January to April 2026

OSF Digital Named a Major Player in IDC MarketScape: Worldwide Salesforce Implementation Services 2025-2026 Vendor Assessment

PR Newswire associated0

Sky Labs Secures CE-MDR for 'CART PLATFORM,' Accelerating Its Global Market Entry

PR Newswire associated0

Droit Launches Decision Decoder

SeeTrue AI screening solution becomes the first and only to receive ECAC certification for Automated Prohibited Items Detection (APIDS)

Arne Boye Nielsen

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors

ACCESS Newswire logo

Market Logic Announces Technology Partnership with Zappi to Accelerate Innovation with AI

PR Newswire associated0

ROBOTERA Showcases Its "Hexa-Core" Robotics Lineup at CES 2026

4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US).

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics

Business Wire logo

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

PR Newswire associated0

CHAGEE Releases "2025 Year-End Tea Friends Review": Global Stores Span 8 Countries Across 2 Continents, Annual Tea Procurement Exceeds 10,000 Tons